The earnings call presented a mixed picture, with significant revenue growth and successful strategic initiatives such as partnerships and cost reductions. However, the company still faces financial challenges with operating and net losses, though these have decreased compared to the previous year.

Company Guidance

During Evogene's Second Quarter 2025 Results Conference Call, the company provided several key financial and operational updates. Total revenues for the first half of 2025 reached approximately $3.2 million, up from $2.3 million in the same period in 2024, driven primarily by strong seed sales from Casterra, a subsidiary. Research and development expenses decreased to approximately $4.8 million from $6.5 million, while sales and marketing expenses fell to $800,000 from $1.1 million, reflecting reduced headcount across subsidiaries. Overall, operating expenses decreased to approximately $7.7 million from $11.1 million. The company reported a consolidated cash and short-term bank deposit balance of $11.7 million as of June 30, 2025. A strategic shift is underway, focusing on maximizing the value of ChemPass AI, an AI-driven discovery platform. Notably, Evogene completed the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL, generating $18.75 million, thereby significantly enhancing cash flow. Future expectations include continued investment in ChemPass AI, expanding collaborations in pharma and agriculture, and operational streamlining to enhance financial stability.

Revenue Growth

Total revenues for the first half of 2025 were approximately $3.2 million, a significant increase from $2.3 million in the first half of 2024, driven by strong seed sales from subsidiary Casterra.

Cost Reduction and Efficiency

Implemented a cost reduction plan, reducing R&D expenses to $4.8 million from $6.5 million and sales and marketing expenses to $800,000 from $1.1 million year-over-year.

Strategic Shift and Partnership with Google Cloud

Completed version 1 of a first-in-class generative AI foundation model for small molecule design in collaboration with Google Cloud, enhancing ChemPass AI's capabilities.

Successful Fundraising

Raised $4.4 million through an at-the-market facility with Lake Street Capital Market, providing a solid financial foundation and an operational runway of approximately 18 months.

Evogene (EVGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EVGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.42 / -	-1.31	―	―	―
Aug 19, 2025	2025 (Q2)	-0.63 / -0.50	-1.06	52.83% (+0.56)	―
May 21, 2025	2025 (Q1)	-0.51 / -0.38	-0.8	52.50% (+0.42)	―
Mar 06, 2025	2024 (Q4)	-0.72 / 0.06	-1.3	104.62% (+1.36)
Nov 21, 2024	2024 (Q3)	-1.01 / -1.31	-0.8	-63.75% (-0.51)	―
Aug 22, 2024	2024 (Q2)	-1.25 / -1.06	-1.7	37.65% (+0.64)	―
May 23, 2024	2024 (Q1)	-0.95 / -0.80	-1.5	46.67% (+0.70)	―
Mar 07, 2024	2023 (Q4)	-1.40 / -1.30	-0.7	-85.71% (-0.60)	―
Nov 15, 2023	2023 (Q3)	-1.57 / -0.80	-1.6	50.00% (+0.80)	―	―
Aug 17, 2023	2023 (Q2)	-1.75 / -1.70	-2.1	19.05% (+0.40)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EVGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 19, 2025	$1.33	$1.27	-4.51%
May 21, 2025	$1.27	$1.18	-7.09%
Mar 06, 2025	$1.41	$1.41	0.00%
Nov 21, 2024	$1.65	$1.60	-3.03%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Evogene (EVGN) report earnings?

Evogene (EVGN) is schdueled to report earning on Nov 12, 2025, TBA (Confirmed).

What is Evogene (EVGN) earnings time?

Evogene (EVGN) earnings time is at Nov 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EVGN EPS forecast?

EVGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.43.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing